The cytosolic isoform of glutaredoxin 2 promotes cell migration and invasion.


Journal

Biochimica et biophysica acta. General subjects
ISSN: 1872-8006
Titre abrégé: Biochim Biophys Acta Gen Subj
Pays: Netherlands
ID NLM: 101731726

Informations de publication

Date de publication:
07 2020
Historique:
received: 15 11 2019
revised: 25 02 2020
accepted: 10 03 2020
pubmed: 17 3 2020
medline: 19 4 2022
entrez: 17 3 2020
Statut: ppublish

Résumé

Cytosolic glutaredoxin 2 (Grx2c) controls axonal outgrowth and is specifically induced in many cancer cell lines. We thus hypothesized that Grx2c promotes cell motility and invasiveness. We characterized the impact of Grx2c expression in cell culture models. We combined stable isotope labeling, phosphopeptide enrichment, and high-accuracy mass spectrometry to characterize the underlying mechanisms. The most prominent associations were found with actin dynamics, cellular adhesion, and receptor-mediated signal transduction, processes that are crucial for cell motility. For instance, collapsin response mediator protein 2, a protein involved in the regulation of cytoskeletal dynamics, is regulated by Grx2c through a redox switch that controls the phosphorylation state of the protein as well. Cell lines expressing Grx2c showed dramatic alterations in morphology. These cells migrated two-fold faster and gained the ability to infiltrate a collagen matrix. The expression of Grx2c promotes cell migration, and may negatively correlate with cancer-specific survival. Our results imply critical roles of Grx2c in cytoskeletal dynamics, cell adhesion, and cancer cell invasiveness.

Identifiants

pubmed: 32173377
pii: S0304-4165(20)30111-2
doi: 10.1016/j.bbagen.2020.129599
pii:
doi:

Substances chimiques

Glutaredoxins 0
Protein Isoforms 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

129599

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflicts of interest.

Auteurs

Manuela Gellert (M)

Institute for Medical Biochemistry and Molecular Biology, University Medicine, University Greifswald, Germany.

Erik Richter (E)

Competence Center Functional Genomics, Junior Research Group Pathoproteomics, University Greifswald, Germany.

Jörg Mostertz (J)

Competence Center Functional Genomics, Junior Research Group Pathoproteomics, University Greifswald, Germany.

Liane Kantz (L)

Center for Innovation Competence plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Greifswald, Germany.

Kai Masur (K)

Center for Innovation Competence plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Greifswald, Germany.

Eva-Maria Hanschmann (EM)

Institute for Medical Biochemistry and Molecular Biology, University Medicine, University Greifswald, Germany.

Silvia Ribback (S)

Institute for Pathology, Germany.

Nils Kroeger (N)

Institute for Medical Biochemistry and Molecular Biology, University Medicine, University Greifswald, Germany; Clinic for Urology, University Medicine Greifswald, Germany.

Elke Schaeffeler (E)

Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tuebingen, Tuebingen, Germany.

Stefan Winter (S)

Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tuebingen, Tuebingen, Germany.

Falko Hochgräfe (F)

Competence Center Functional Genomics, Junior Research Group Pathoproteomics, University Greifswald, Germany.

Matthias Schwab (M)

Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Departments of Clinical Pharmacology, and Pharmacy and Biochemistry, University of Tuebingen, Tuebingen, Germany.

Christopher Horst Lillig (CH)

Institute for Medical Biochemistry and Molecular Biology, University Medicine, University Greifswald, Germany. Electronic address: horst@lillig.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH